Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Aridis Pharmaceuticals withdraws proposed public offering of common stock » 09:21
09/27/22
09/27
09:21
09/27/22
09:21
ARDS

Aridis Pharmaceuticals

/

+

Aridis Pharmaceuticals…

Aridis Pharmaceuticals announced that due to adverse market conditions, it has withdrawn its proposed public offering of shares of its common stock. "Due to the current market environment and in the interest of achieving the best value for our stockholders, we have decided to withdraw our recently announced public offering of common stock and focus on executing our clinical development plans," said Vu Truong, CEO of Aridis.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
/

+

ARDS Aridis Pharmaceuticals
/

+

08/16/22 Maxim
Aridis Pharmaceuticals downgraded to Hold from Buy at Maxim
01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
ARDS Aridis Pharmaceuticals
/

+

Monday
Syndicate
Aridis Pharmaceuticals to offer common stock, no amount given » 15:39
09/26/22
09/26
15:39
09/26/22
15:39
ARDS

Aridis Pharmaceuticals

$1.21 /

-0.02 (-1.63%)

Aridis Pharmaceuticals…

Aridis Pharmaceuticals announced that it intends to offer its common stock in a public offering. "The company intends to use the net proceeds from this offering for clinical development of our product candidates, working capital and other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering," Aridis stated. Aegis Capital is acting as the sole book-running manager for the offering.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$1.21 /

-0.02 (-1.63%)

ARDS Aridis Pharmaceuticals
$1.21 /

-0.02 (-1.63%)

08/16/22 Maxim
Aridis Pharmaceuticals downgraded to Hold from Buy at Maxim
01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
ARDS Aridis Pharmaceuticals
$1.21 /

-0.02 (-1.63%)

Over a week ago
Syndicate
Aridis Pharmaceuticals files $100M mixed securities shelf  17:30
09/02/22
09/02
17:30
09/02/22
17:30
ARDS

Aridis Pharmaceuticals

$1.50 /

+0.055 (+3.81%)

 
ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$1.50 /

+0.055 (+3.81%)

ARDS Aridis Pharmaceuticals
$1.50 /

+0.055 (+3.81%)

08/16/22 Maxim
Aridis Pharmaceuticals downgraded to Hold from Buy at Maxim
01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
ARDS Aridis Pharmaceuticals
$1.50 /

+0.055 (+3.81%)

Over a month ago
Earnings
Aridis Pharmaceuticals reports Q2 EPS (45c), consensus (6c) » 16:19
08/16/22
08/16
16:19
08/16/22
16:19
ARDS

Aridis Pharmaceuticals

$2.03 /

-0.16 (-7.31%)

Reports Q2 revenue…

Reports Q2 revenue $292,000, consensus $10.46M. Total cash, cash equivalents and restricted cash as of June 30 were approximately $8.0M. "The company is on track to report top-line data from the AR-301 Phase 3 study in ventilator associated pneumonia (VAP) and the AR-501 Phase 2a study in cystic fibrosis during the second half of 2022," commented Vu Truong, CEO. "We believe these data readouts will be significant and transformative milestones for the Company. In addition, we completed the manufacturing of the clinical trial supplies and launched the global Phase 3 trial of AR-320."

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$2.03 /

-0.16 (-7.31%)

ARDS Aridis Pharmaceuticals
$2.03 /

-0.16 (-7.31%)

08/16/22 Maxim
Aridis Pharmaceuticals downgraded to Hold from Buy at Maxim
01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
Downgrade
Aridis Pharmaceuticals downgraded to Hold from Buy at Maxim » 09:47
08/16/22
08/16
09:47
08/16/22
09:47
ARDS

Aridis Pharmaceuticals

$2.19 /

+ (+0.00%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy downgraded Aridis Pharmaceuticals to Hold from Buy.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$2.19 /

+ (+0.00%)

ARDS Aridis Pharmaceuticals
$2.19 /

+ (+0.00%)

01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
11/11/21 Northland
Aridis Pharmaceuticals price target lowered to $10 from $22 at Northland
Hot Stocks
Aridis Pharmaceuticals' AR-701 cocktail shows anti-COVID protection in primates » 08:34
08/10/22
08/10
08:34
08/10/22
08:34
ARDS

Aridis Pharmaceuticals

$2.21 /

-0.08 (-3.49%)

Aridis Pharmaceuticals…

Aridis Pharmaceuticals announced that inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in the lungs of infected rhesus macaques, and protected their lungs from disease. AR-701 was effective in the non-human primates when used either as a prophylactic or therapeutic treatment regimen. Therapeutic administration of inhaled AR-701 substantially reduced and continued to suppress the viral load in the nasal sinus and oropharynx for the entire 5-day testing period. Additional lab research also indicates both mAbs in the AR-701 cocktail are effective against the SARS-CoV-2 Omicron BA.1, BA.2, BA.4, BA.5 subvariants in vitro. Preliminary study results were recently presented at the Immunotherapy for Infectious Diseases Conference 2022 in Pavia, Italy. Additional data are being analyzed and will be submitted to a peer-reviewed scientific journal for publication. AR-701 is a cocktail of two fully human immunoglobulin G1 mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 - COVID-19 - infected patients.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$2.21 /

-0.08 (-3.49%)

ARDS Aridis Pharmaceuticals
$2.21 /

-0.08 (-3.49%)

01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
11/11/21 Northland
Aridis Pharmaceuticals price target lowered to $10 from $22 at Northland
Over a quarter ago
Conference/Events
Aridis Pharmaceuticals participates in a conference call with Maxim » 04:55
06/07/22
06/07
04:55
06/07/22
04:55
ARDS

Aridis Pharmaceuticals

$1.06 /

+0.01 (+0.95%)

Analyst McCarthy holds a…

Analyst McCarthy holds a conference call with CEO Truong will be held on June 7 hosted by Maxim.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$1.06 /

+0.01 (+0.95%)

ARDS Aridis Pharmaceuticals
$1.06 /

+0.01 (+0.95%)

01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
11/11/21 Northland
Aridis Pharmaceuticals price target lowered to $10 from $22 at Northland
Conference/Events
Aridis Pharmaceuticals participates in a conference call with Maxim » 15:22
05/31/22
05/31
15:22
05/31/22
15:22
ARDS

Aridis Pharmaceuticals

$1.15 /

+0.05 (+4.55%)

Analyst McCarthy holds a…

Analyst McCarthy holds a conference call with CEO Truong will be held on June 7 hosted by Maxim.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$1.15 /

+0.05 (+4.55%)

ARDS Aridis Pharmaceuticals
$1.15 /

+0.05 (+4.55%)

01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
11/11/21 Northland
Aridis Pharmaceuticals price target lowered to $10 from $22 at Northland
Hot Stocks
Aridis Pharmaceuticals says both mAbs in AR-701 neutralized omicron variant » 06:52
02/17/22
02/17
06:52
02/17/22
06:52
ARDS

Aridis Pharmaceuticals

$2.61 /

+0.14 (+5.67%)

Aridis Pharmaceuticals…

Aridis Pharmaceuticals announced that both of its fully human monoclonal antibodies, or mAbs, in the AR-701 cocktail neutralized the SARS-CoV-2 omicron variant. Moreover, both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, neutralized all authentic SARS-CoV-2 beta, gamma, delta, epsilon, and Omicron variants in vitro. Both mAbs of the AR-701 cocktail, when used either individually or in combination, conferred complete eradication of virus from Omicron infected mice and protection against disease pathology. Aridis Pharmaceuticals has recently received a $1.9M grant from the Bill and Melinda Gates Foundation to evaluate the prevention of influenza and SARS-CoV-2 viral transmission using inhaled delivery of monoclonal antibodies.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$2.61 /

+0.14 (+5.67%)

ARDS Aridis Pharmaceuticals
$2.61 /

+0.14 (+5.67%)

01/27/22 H.C. Wainwright
H.C. Wainwright bullish on Aridis after funding from Gates Foundation
12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
11/11/21 Northland
Aridis Pharmaceuticals price target lowered to $10 from $22 at Northland
ARDS Aridis Pharmaceuticals
$2.61 /

+0.14 (+5.67%)

ARDS Aridis Pharmaceuticals
$2.61 /

+0.14 (+5.67%)

Recommendations
H.C. Wainwright bullish on Aridis after funding from Gates Foundation » 10:06
01/27/22
01/27
10:06
01/27/22
10:06
ARDS

Aridis Pharmaceuticals

$2.20 /

+0.46 (+26.44%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Vernon Bernardino notes that Aridis Pharmaceuticals announced it received a grant award from the Bill & Melinda Gates Foundation to evaluate application of Aridis' inhaled biologics formulation technology to deliver cost-effective monoclonal antibodies against influenza and SARSCoV2 to people in low- and middle-income countries. The analyst is positive on the news, as he believes support from BMGF is strong validation of the potential of Aridis' formulation technology, which enables self-administration of prophylactic and therapeutic antibodies directly to the upper or lower airways of the respiratory tract. Further, Bernandino thinks the company's technology could enhance bioavailability of mAbs to the site where respiratory viruses initially infect, replicate, and shed to disseminate through person-to-person transmission. The analyst has a Buy rating and a price target of $19 on the shares.

ShowHide Related Items >><<
ARDS Aridis Pharmaceuticals
$2.20 /

+0.46 (+26.44%)

ARDS Aridis Pharmaceuticals
$2.20 /

+0.46 (+26.44%)

12/29/21 H.C. Wainwright
Aridis has potential first-in-class monoclonal antibody, says H.C. Wainwright
12/21/21 Cantor Fitzgerald
Aridis Pharmaceuticals' pipeline 'underappreciated,' says Cantor Fitzgerald
11/11/21 Northland
Aridis Pharmaceuticals price target lowered to $10 from $22 at Northland
07/20/21 H.C. Wainwright
Aridis Pharmaceuticals price target raised to $19 from $11 at H.C. Wainwright
ARDS Aridis Pharmaceuticals
$2.20 /

+0.46 (+26.44%)

ARDS Aridis Pharmaceuticals
$2.20 /

+0.46 (+26.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.